Clinical Trials Logo

Skin Diseases, Papulosquamous clinical trials

View clinical trials related to Skin Diseases, Papulosquamous.

Filter by:
  • None
  • Page 1

NCT ID: NCT06099080 Active, not recruiting - Clinical trials for Dermatosis Papulosa Nigra

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)

Start date: November 7, 2023
Phase: Phase 2
Study type: Interventional

An open-label trial to explore the safety and efficacy of SM-020 gel 1.0% in subjects with Dermatosis Papulosa Nigra (DPN). Approximately 10 subjects will be enrolled with DPNs to apply SM-020 gel 1.0%. Each subject must have a minimum of 5 eligible DPNTLs with a diameter ≥2mm but ≤5mm. A maximum of 10 DPNs per subject will be targeted for treatment. Subjects will apply the investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12 weeks post final application for a total of approximately 16 weeks of required participation in the study. A total of 5-10 eligible Dermatosis Papulosa Nigra Target Lesions (DPNTLs) will be treated per subject.

NCT ID: NCT05185258 Active, not recruiting - Psoriasis Clinical Trials

Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study

MEMPSOLAR
Start date: February 16, 2022
Phase: Phase 4
Study type: Interventional

Psoriasis is a non-communicable chronic immune-mediated disease. Psoriatic skin is characterized by excessive proliferation of skin cells and infiltration of immune cells. The cause of psoriasis is so far unknown. Established therapeutics include topical, oral-systemic, biologic, narrow-band ultraviolet B (NB-UVB). A persistent antipsoriatic effect by the newest biologic therapies has been demonstrated after treatment discontinuation. However, the remittive hallmark of psoriasis suggests the existence of a molecular scar, a kind of disease memory, in clinically healed skin. It has been suggested that this disease memory can be attributed to the tissue-resident memory T (TRM) cell. The main purpose of the study is to investigate whether (NB-UVB) treatment and concomitant Enstilar® treatment can change the amount of TRMs in the skin as well as change the expression in the microenvironment around these cells in the skin from psoriasis patients. In addition, the investigators will investigate whether the treatment can change the quantity and types of other psoriasis-related cells in the skin. In addition to this, the investigators will also examine the effect of treatment on patient-related parameters.

NCT ID: NCT03224598 Completed - Clinical trials for Dermatosis Papulosa Nigra

A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

Start date: June 26, 2017
Phase: Phase 2
Study type: Interventional

Evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.

NCT ID: NCT03156062 Not yet recruiting - Clinical trials for Papulosquamous Skin Disease

Climatotherapy Versus Topical Combination of Corticosteroids and Salicylic Acid in Treatment of Psoriasis

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

Psoriasis is a multisystem disease predominately manifested as chronic inflammation of the skin and characterized by scaly, erythematous patches, papules and plaques, which are often pruritic. As chronic disease, psoriasis waxes and wanes throughout patient life time. The disease course is modified with initiation and cessation of treatment, and spontaneous remission is rare. Clinically lesions can be distributed in any part of the body, this leads to impaired consequences on the perception of body image, social relations and in general on quality of life.

NCT ID: NCT01938599 Completed - Plaque Psoriasis Clinical Trials

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

Start date: August 2013
Phase: Phase 2
Study type: Interventional

To compare the safety and efficacy profile of AM001 Cream and its vehicle in the treatment of plaque psoriasis.

NCT ID: NCT01490632 Completed - Psoriasis Clinical Trials

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

Start date: December 2011
Phase: Phase 2
Study type: Interventional

This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety assessments.

NCT ID: NCT00710203 Completed - Clinical trials for Seborrheic Keratoses

Dermatosis Papulosa Nigra

DPN
Start date: July 2008
Phase: N/A
Study type: Interventional

DPN is a disorder among darkly pigmented patients, manifested by small, benign, variants of seborrheic keratoses, predominantly on the face. The purpose of this study is to determine the efficacy of a 585 nm PDL for the treatment of Dermatosis Papulosa Nigra, and compare it to therapy with curettage (scraping the lesions off) and electrodesiccation (burning the lesions off).

NCT ID: NCT00293722 Completed - Psoriasis Clinical Trials

Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists

Start date: January 2006
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the safety and effectiveness of etanercept under usual care settings in patients with PsA treated by rheumatologists.

NCT ID: NCT00293709 Completed - Psoriasis Clinical Trials

Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists

Start date: January 2006
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the safety profile and the effectiveness of etanercept under usual care settings in patients with PsA treated by dermatologists.